论文部分内容阅读
目的:观察那格列奈治疗70岁以上2型糖尿病人的疗效及安全性。方法:70岁以上2型糖尿病患者95例,治疗前未用过任何降糖药物,在适当控制饮食的基础上,随机分为两组。观察组46例予那格列奈片60～180 mg/次,起始剂量120mg,三餐前1～15 min口服;对照组49人,予瑞格列奈片0.5～2 mg/次,起始剂量1 mg,三餐前1～15 min口服。共治疗12周。观察空腹、餐后2 h血糖,HbA1c,TG,TC,体重,低血糖发生率。结果:治疗后,两组患者FBG、PBG、HbA1c,TG、TC均较治疗前明显下降(P<0.01)。而治疗后两比较,差异无统计学意义(P>0.05)。观察组发生低血糖1例(2.2%);对照组发生7例(14.3%),两组差异有统计学意义(P<0.05)。结论:那格列奈对70岁以上2型糖尿病患者降糖效果确切,安全。
Objective: To observe the efficacy and safety of nateglinide in the treatment of type 2 diabetes mellitus in people over 70 years old. Methods: 95 cases of type 2 diabetes mellitus were over 70 years old. Before treatment, no hypoglycemic drugs were used. On the basis of proper diet control, they were randomly divided into two groups. In the observation group, 46 cases were treated with nateglinide 60 ~ 180 mg / time, the initial dose 120 mg orally 1 ~ 15 minutes before meals. In the control group, 49 patients received repaglinide 0.5 ~ 2 mg / The initial dose of 1 mg, oral meal before 1 ~ 15 min. A total of 12 weeks of treatment. Fasting, postprandial blood glucose 2 h, HbA1c, TG, TC, body weight, incidence of hypoglycemia. Results: After treatment, FBG, PBG, HbA1c, TG and TC in both groups were significantly lower than those before treatment (P <0.01). After treatment, the difference was not statistically significant (P> 0.05). Hypoglycemia occurred in 1 case (2.2%) in observation group and in control group (7 cases) (14.3%). There was significant difference between the two groups (P <0.05). Conclusion: Nateglinide has definite and safe hypoglycemic effect on type 2 diabetic patients over 70 years old.